Enlivex Therapeutics Ltd. (ENLV)

Last Closing Price: 2.65 (2023-06-02)

Company Description

Enlivex is a clinical stage immunotherapy company, developing an allogeneic drug pipeline for immune system rebalancing. Immune system rebalancing is critical for the treatment of life-threatening immune and inflammatory conditions which involve hyper-expression of cytokines (Cytokine Release Syndrome) and for which there are no approved treatments (unmet medical needs), as well as solid tumors immune-checkpoint rebalancing.

Financials, Fundamental Metrics & Ratios
Revenue (Most Recent Fiscal Year) --
Net Income (Most Recent Fiscal Year) $-31.06M
PE Ratio (Current Year Earnings Estimate) --
PE Ratio (Trailing 12 Months) --
PEG Ratio (Long Term Growth Estimate) --
Price to Sales Ratio (Trailing 12 Months) --
Price to Book Ratio (Most Recent Quarterly Book Value per Share) 0.86
Price to Cash Ratio (Most Recent Annual Cash Flow per Share) --
Pre-Tax Margin (Trailing 12 Months) --
Net Margin (Trailing 12 Months) --
Return on Equity (Trailing 12 Months) -46.66%
Return on Assets (Trailing 12 Months) -40.60%
Current Ratio (Most Recent Fiscal Quarter) 7.92
Quick Ratio (Most Recent Fiscal Quarter) 7.92
Debt to Common Equity (Most Recent Fiscal Quarter) 0.00
Inventory Turnover (Trailing 12 Months) --
Book Value per Share (Most Recent Fiscal Quarter) $3.09
Earnings per Share (Most Recent Fiscal Quarter) $-0.39
Earnings per Share (Most Recent Fiscal Year) $-1.69
Diluted Earnings per Share (Trailing 12 Months) $-1.69
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Common Shares Outstanding 18.57M
Free Float 16.29M
Market Capitalization $49.11M
Average Volume (Last 20 Days) 0.02M
Beta (Past 60 Months) 0.93
Percentage Held By Insiders (Latest Annual Proxy Report) 12.28%
Percentage Held By Institutions (Latest 13F Reports) 1.82%
Annual Dividend (Based on Last Quarter) $0.00
Dividend Yield (Based on Last Quarter) 0.00%